Mirimus Revenue and Competitors

At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus' advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease.